本文關(guān)鍵詞：乳腺癌患者中血清性激素水平與甲狀腺腫瘤的相關(guān)性研究　出處：《廣西醫(yī)科大學(xué)》2017年碩士論文　論文類(lèi)型：學(xué)位論文

  更多相關(guān)文章： 性激素 乳腺癌 甲狀腺腫瘤 甲狀腺彩超

【摘要】：目的:探討在乳腺癌患者中,血清性激素水平與甲狀腺腫瘤之間的相互關(guān)系及其臨床意義。方法:收集廣西醫(yī)科大學(xué)附屬腫瘤醫(yī)院2013年11月至2016年11月60例初診乳腺癌并同時(shí)經(jīng)甲狀腺彩超發(fā)現(xiàn)甲狀腺腫瘤的患者,作為乳腺癌合并甲狀腺腫瘤組;收集同時(shí)期年齡、體重指數(shù)、月經(jīng)狀況、初潮年齡及孕次相匹配的初診單純性乳腺癌患者60例,作為單純性乳腺癌組,該組所有患者截至隨訪日期前經(jīng)B超或CT檢查亦無(wú)甲狀腺腫瘤發(fā)生;對(duì)兩組患者初始治療前采用化學(xué)發(fā)光法檢測(cè)的雌激素(E2)、孕激素(P)、泌乳素(PRL)、卵泡刺激素(FSH)、黃體生成素(LH)及睪酮(T)水平進(jìn)行回顧性分析;根據(jù)甲狀腺彩超對(duì)甲狀腺腫瘤的檢查結(jié)果,按甲狀腺腫瘤大小(是否大于1cm)、單發(fā)或多發(fā)及是否有惡性征象進(jìn)行分組,進(jìn)一步比較性激素水平與乳腺癌中的甲狀腺腫瘤臨床特征(大小、單發(fā)或多發(fā)及是否有惡性征象)之間的關(guān)系。統(tǒng)計(jì)學(xué)分析采用t檢驗(yàn)及非參數(shù)秩和檢驗(yàn)。結(jié)果:乳腺癌合并甲狀腺腫瘤組與單純性乳腺癌組患者的各項(xiàng)性激素水平比較結(jié)果顯示:乳腺癌合并甲狀腺腫瘤組E2水平中位數(shù)較單純性乳腺癌組高,差異有統(tǒng)計(jì)學(xué)意義(P=0.03);乳腺癌合并甲狀腺腫瘤組PRL水平較單純性乳腺癌組低,差異有統(tǒng)計(jì)學(xué)意義(P=0.001)。而P、FSH、LH及T水平兩組之間差異無(wú)統(tǒng)計(jì)學(xué)意義(P值分別為0.109、0.337、0.295、0.104,P0.05)。對(duì)乳腺癌中的甲狀腺腫瘤大小(是否大于1cm)、單發(fā)多發(fā)及是否有惡性征象進(jìn)行分組,各組之間的E2、PRL水平差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:1、乳腺癌合并甲狀腺腫瘤患者和單純性乳腺癌患者相比,血清E2水平升高,PRL水平降低,提示E2及PRL水平的變化可能與甲狀腺腫瘤的發(fā)生有關(guān)。2、乳腺癌并發(fā)甲狀腺腫瘤時(shí),血清E2與PRL水平與甲狀腺腫瘤的大小、單發(fā)多發(fā)及是否有惡性征象之間無(wú)明顯相關(guān)性。
[Abstract]:Objective: to explore the diagnosis of breast cancer. The relationship between serum sex hormone level and thyroid tumor and its clinical significance. Methods:. From November 2013 to November 2016, 60 patients with breast cancer were collected from affiliated Cancer Hospital of Guangxi Medical University. As a group of breast cancer with thyroid neoplasms; A total of 60 patients with primary breast cancer who were matched with age, BMI, menstrual status, menarche age and pregnancy were collected as simple breast cancer group. All patients in this group had no thyroid neoplasms by B-ultrasonography or CT before the follow-up date. The estradiol, progesterone, prolactin (PRL) and follicle stimulating hormone (FSHs) were detected by chemiluminescence before initial treatment in both groups. The levels of luteinizing hormone (LH) and testosterone (T) were analyzed retrospectively. According to the results of thyroid tumors by thyroid color Doppler ultrasound, the thyroid tumors were grouped according to their size (> 1 cm), single or multiple, and malignant signs. To further compare sex hormone levels with the clinical features of thyroid tumors in breast cancer. Single or multiple and malignant signs). T test and nonparametric rank sum test were used in statistical analysis. Results: sex hormone levels in patients with breast cancer combined with thyroid neoplasms were compared with those in patients with simple breast cancer. The median E _ 2 level in breast cancer with thyroid neoplasms was higher than that in simple breast cancer. The difference was statistically significant (P < 0. 03). The level of PRL in breast cancer with thyroid tumor group was lower than that in simple breast cancer group, the difference was statistically significant. There was no significant difference in LH and T levels between the two groups (P = 0.109) and 0.337U 0.295 (0.104), respectively. P0.05. the size of thyroid tumor in breast cancer (> 1 cm), single multiple and malignant signs were divided into groups, E2 among each group. There was no significant difference in serum E 2 level between breast cancer patients with thyroid tumor and simple breast cancer patients (P 0.05). Conclusion compared with simple breast cancer patients, serum E 2 level is higher and lower than that in breast cancer patients with thyroid neoplasms. These results suggest that the changes of E2 and PRL levels may be related to the occurrence of thyroid neoplasms. The serum E2 and PRL levels and the size of thyroid neoplasms may be related to the occurrence of thyroid tumors in breast cancer. There was no significant correlation between single multiple and malignant signs.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R737.9;R736.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 尹樹(shù)慧;趙文龍;曹海霞;;女性甲狀腺功能異常者血清性激素水平的變化分析[J];中國(guó)現(xiàn)代醫(yī)藥雜志;2017年03期

2 高麗霞;張益枝;吳克雄;胡軍;冀紅紅;張學(xué)平;賈曉玲;林英;;乳腺癌患者甲狀腺功能的相關(guān)研究[J];現(xiàn)代腫瘤醫(yī)學(xué);2016年07期

3 胡悅;孫超;地力木拉提·艾斯木吐拉;欒梅香;;甲狀腺功能異常與乳腺良惡性腫瘤關(guān)系探討[J];中國(guó)普外基礎(chǔ)與臨床雜志;2015年10期

4 韓晴;黃漢林;;甲狀腺疾病影響因素研究進(jìn)展[J];中國(guó)職業(yè)醫(yī)學(xué);2015年03期

5 吳萬(wàn)敏;張艷;;乳腺癌中THRβ1表達(dá)與甲狀腺激素改變的臨床研究[J];臨床和實(shí)驗(yàn)醫(yī)學(xué)雜志;2014年18期

6 柳林;盧洪文;馮劍;劉長(zhǎng)山;;健康體檢者7097名甲狀腺結(jié)節(jié)檢出情況與臨床特點(diǎn)[J];中華臨床醫(yī)師雜志(電子版);2014年14期

7 鄭瑩;吳春曉;張敏璐;;乳腺癌在中國(guó)的流行狀況和疾病特征[J];中國(guó)癌癥雜志;2013年08期

8 康維明;吳戀;于健春;馬志強(qiáng);高維生;;北京協(xié)和醫(yī)院1986～2012年甲狀腺疾病手術(shù)患者甲狀腺疾病譜回顧性臨床資料分析[J];中國(guó)醫(yī)學(xué)科學(xué)院學(xué)報(bào);2013年04期

9 張?jiān)品?秦貴軍;馬笑X;;女性甲狀腺功能異常患者性激素水平變化分析[J];實(shí)用醫(yī)藥雜志;2013年05期

10 趙艷杰;王睿斌;宋雨光;任軍;;乳腺癌與甲狀腺疾病相關(guān)性的臨床研究[J];腫瘤研究與臨床;2013年03期

，

本文編號(hào)：1401501